SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE) -- Sequenta, Inc. today announced that the sample types eligible for analysis with its ClonoSIGHT™ minimal residual disease (MRD) test for leukemia and lymphoma have been expanded to include formalin-fixed, paraffin-embedded (FFPE) tissue and bone marrow aspirate slides. This advancement allows the test to be performed on the diagnostic samples most commonly available from pathology labs.
The ClonoSIGHT MRD test uses Sequenta’s proprietary LymphoSIGHT™ platform, which works by sequencing unique DNA signatures present in immune cells, to identify cancer cell clones in diagnostic samples and then detect and track the resurgence of these cells after treatment. The sequencing-based readout provides quantitative results that can be directly interpreted by oncologists. Testing for MRD can help determine whether treatment has been successful, provide important information about patient prognosis and help guide additional treatment decisions.
“We are pleased to be able to offer increased sample type flexibility to physicians treating patients with leukemia and lymphoma,” said Tom Willis, chief executive officer at Sequenta. “Advancing our product to handle these technically difficult sample types greatly expands the number of patients who can benefit from sequencing-based residual disease testing and underscores our commitment to making the ClonoSIGHT test the clinical standard for all lymphoid cancers.”
The ClonoSIGHT test, the first clinically actionable sequencing-based test for MRD in leukemia and lymphoma, has been shown to offer unprecedented sensitivity for the detection of residual cancer cells in bone marrow or blood. The LymphoSIGHT platform can detect malignant sub-populations of cells even when they are present at levels as low as one cell per million white blood cells. Test results are generated in seven days using Sequenta’s CLIA-certified laboratory.
Sequenta is a venture-backed biotechnology company dedicated to improving patient care in diseases mediated by immune cells through the discovery and development of novel clinical diagnostics. The company is commercializing its LymphoSIGHT™ platform for clinical use in minimal residual disease in leukemia and lymphoma, while continuing to validate the use of its technology in a diverse set of diseases. For more information, please visit www.sequenta.com.